Jude Samulski's gene therapy company just raised $235M for clinical development
A gene therapy company that’s played a key role in backing treatments now owned by Novartis and Pfizer is stepping up this morning with a monster venture raise aimed at making it a leading clinical developer in one of the hottest fields in biotech.
Asklepios Biopharmaceutical, which prefers to be less formally known as AskBio, sold a minority stake in the company to TPG and Vida Ventures for $225 million. And the company’s founders and board members are putting in another $10 million — skin in the game.
Basic subscription required
Unlock this story instantly and join 53,100+ biopharma pros reading Endpoints daily — and it's free.